Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...
Patient 1, a 58-year-old man, received eight cycles of intravenous bortezomib followed by combination bortezomib and lenalidomide, and he had only a partial response. He underwent autologous stem-cell ...
PURPOSE: To evaluate the natural history of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), identify early predictors of evolution, and assess whether ...
Background: Diagnosis of monoclonal gammopathies (MGs) is determined by demonstration of a monoclonal immunoglobulin molecule or chain in serum and/or urine. Previous results on immunofixation ...
In a systematically screened population, there is no association between autoimmune disease and monoclonal gammopathy of undetermined significance (MGUS), according to a study published online May 21 ...
Monoclonal gammopathy of undetermined significance (MGUS) is when small amounts of antibodies called monoclonal antibodies (or M antibodies) are found in your blood. Normally, the plasma cells in your ...
While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not have an impact on overall survival in patients with chronic lymphocytic leukemia (CLL). Patients with ...
The rate of MGUS among hospitalized patients over 50 was twice as high as that of the same age group in the general population. Higher rates of MGUS were prevalent among patients who had elevated ...
Monoclonal gammopathy of undetermined significance (MGUS) is an abnormal finding of a blood test. It means there’s a specific protein present in your blood and is an early sign of certain types of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results